Sonosensitizer-Functionalized Graphene Nanoribbons for Adhesion Blocking and Sonodynamic Ablation of Ovarian Cancer

Hak Rae Lee1, Dae Woo Kim2, Victoria O Jones1

  • 1Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN, 55455, USA.

Insights

This study introduces graphene nanoribbons (GNR) functionalized with polyethylene glycol (PEG) and chlorin e6 (Ce6) to treat ovarian cancer spheroids. This novel therapeutic agent inhibits metastasis and enhances chemotherapy and sonodynamic treatments.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Oncology

Background:

  • Advanced ovarian cancer is difficult to treat due to widespread peritoneal metastasis.
  • Ovarian cancer spheroids resist conventional therapies and promote disease spread.

Purpose of the Study:

  • To develop a targeted therapeutic agent for metastatic ovarian cancer spheroids.
  • To evaluate the efficacy of graphene nanoribbons (GNR) functionalized with polyethylene glycol (PEG) and chlorin e6 (Ce6) in inhibiting spheroid adhesion and enhancing treatment outcomes.

Main Methods:

  • GNR-PEG-Ce6 was synthesized and characterized.
  • The agent's effect on ovarian cancer spheroid adhesion to mesothelial cells and extracellular matrix was assessed.
  • Sonodynamic therapy and combination chemotherapy (cisplatin, paclitaxel) efficacy were evaluated in vitro.
  • Experiments were validated using patient-derived ascites tumor spheroids.

Main Results:

  • GNR-PEG-Ce6 effectively inhibited spheroid adhesion and spreading.
  • Localized sonodynamic therapy with GNR-PEG-Ce6 eradicated adhered spheroids.
  • The agent sensitized spheroids to cisplatin and paclitaxel by loosening cell-cell adhesions.
  • Therapeutic effects were confirmed in patient-derived spheroids.

Conclusions:

  • GNR-PEG-Ce6 is a promising biomaterial for targeting ovarian cancer metastasis.
  • This approach facilitates effective combination therapy, integrating sonodynamic and chemotherapeutic strategies.
  • The findings demonstrate significant translational potential for treating advanced ovarian cancer.

Related Concept Videos